Total Payments
$2.5M
2024 Payments
$94,098
Companies
7
Transactions
850
Medicare Patients
4,861
Medicare Billing
$187,576
Payment Breakdown by Category
Research$1.3M (53.9%)
Consulting$1.1M (46.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 80 | 53.9% |
| Consulting Fee | $1.1M | 770 | 46.1% |
Payments by Type
Research
$1.3M
80 transactions
General
$1.1M
770 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1.3M | 77 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $1.0M | 739 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $70,555 | 17 | $0 (2023) |
| PFIZER INC. | $46,515 | 12 | $0 (2024) |
| Eli Lilly and Company | $18,240 | 2 | $0 (2018) |
| Boehringer Ingelheim International GmbH | $13,685 | 2 | $0 (2023) |
| Genentech, Inc. | $3,750 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $94,098 | 20 | E.R. Squibb & Sons, L.L.C. ($47,583) |
| 2023 | $236,315 | 24 | E.R. Squibb & Sons, L.L.C. ($155,725) |
| 2022 | $173,608 | 17 | E.R. Squibb & Sons, L.L.C. ($169,958) |
| 2021 | $475,883 | 199 | Merck Sharp & Dohme Corporation ($263,580) |
| 2020 | $497,193 | 214 | Merck Sharp & Dohme Corporation ($261,858) |
| 2019 | $439,413 | 154 | E.R. Squibb & Sons, L.L.C. ($283,500) |
| 2018 | $318,588 | 119 | E.R. Squibb & Sons, L.L.C. ($221,460) |
| 2017 | $257,351 | 103 | Merck Sharp & Dohme Corporation ($240,971) |
All Payment Transactions
850 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $5,570.00 | General |
| 12/12/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| 11/26/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $10,845.00 | General |
| 10/23/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $6,625.00 | General |
| 10/18/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 09/20/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $4,385.00 | General |
| 08/22/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $4,170.00 | General |
| 07/11/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $3,910.00 | General |
| 06/13/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $4,335.00 | General |
| 05/29/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 05/08/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $75.00 | Research |
| Study: An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (CheckMate 9X8) • Category: Oncology | ||||||
| 04/12/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $660.00 | General |
| 03/22/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $765.00 | General |
| 01/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $12,540.00 | Research |
| Study: Phase III MSI High CRC (142 PMR) - A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair D • Category: Oncology | ||||||
| 01/04/2024 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $12,000.00 | Research |
| Study: Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS & 9th DMC) | ||||||
| 01/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $8,610.00 | Research |
| Study: Phase III Nivo+Ipi vs Placebo in Adjuvant RCC (Part B FA) - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Par • Category: Oncology | ||||||
| 01/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $4,695.00 | Research |
| Study: Phase III 1L Gastric (nivo+ipi vs nivo+CT vs CT) • Category: Oncology | ||||||
| 01/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $4,500.00 | Research |
| Study: Phase III Nivo+Ipi Combo in 1L Bladder (FA = OS Primary Study Cis-Ineligible) • Category: Oncology | ||||||
| 01/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $3,962.50 | Research |
| Study: Phase II Nivo orc Nivo combo in mCRC MSI-H & non MSI-H - A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon Cancer • Category: Oncology | ||||||
| 01/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $1,200.00 | Research |
| Study: Phase III 1L Esophageal (Nivo+Ipi vs Nivo+CT vs CT) • Category: Oncology | ||||||
| 12/01/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,045.00 | General |
| 11/01/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,935.00 | General |
| 10/02/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $9,375.00 | General |
| 10/02/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $5,735.00 | General |
| 09/01/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $7,950.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase III 1L Gastric nivo ipi vs nivo CT vs CT | E.R. Squibb & Sons, L.L.C. | $245,490 | 5 |
| Phase III Nivo Ipi Combo in 1L Bladder | E.R. Squibb & Sons, L.L.C. | $129,375 | 4 |
| Phase IIB Colon Cancer MSI nivo mono and combo | E.R. Squibb & Sons, L.L.C. | $110,240 | 5 |
| Phase III 1L Esophageal Nivo Ipi vs Nivo CT vs CT | E.R. Squibb & Sons, L.L.C. | $94,140 | 5 |
| Phase IIB MSI High CRC PMR | E.R. Squibb & Sons, L.L.C. | $70,695 | 3 |
| Phase III Nivo Ipi vs Placebo in Adjuvant RCC | E.R. Squibb & Sons, L.L.C. | $70,455 | 4 |
| Phase III MSI High CRC (142 PMR) - A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair D | E.R. Squibb & Sons, L.L.C. | $54,615 | 2 |
| Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo | E.R. Squibb & Sons, L.L.C. | $53,865 | 4 |
| Phase II III 1L CRC Nivo CT w pt segmentation rational combos | E.R. Squibb & Sons, L.L.C. | $49,410 | 4 |
| Phase III Nivo Ipi vs Placebo in Adjuvant RCC - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrec | E.R. Squibb & Sons, L.L.C. | $48,405 | 1 |
| Phase III Nivo+Ipi vs Placebo in Adjuvant RCC (Part B FA) - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Par | E.R. Squibb & Sons, L.L.C. | $46,140 | 2 |
| Phase IIIB MSI High CRC PMR - A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Defici | E.R. Squibb & Sons, L.L.C. | $40,035 | 1 |
| Phase IIB Signal Detection Single arm, PD-1 TNBC, SCLC, pancreatic, gastric, bladder, Ovarian Mono and Combo | E.R. Squibb & Sons, L.L.C. | $35,240 | 3 |
| Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS) | E.R. Squibb & Sons, L.L.C. | $31,815 | 1 |
| Phase III 1L Combo SCLC Consolidation LD ED non-progressors | E.R. Squibb & Sons, L.L.C. | $30,075 | 3 |
| Phase III Nivo+Ipi Combo in 1L Bladder (FA = OS Primary Study Cis-Ineligible) | E.R. Squibb & Sons, L.L.C. | $27,930 | 2 |
| Phase III 1L Combo SCLC Consolidation LD ED non progressors | E.R. Squibb & Sons, L.L.C. | $25,500 | 1 |
| Phase IIB Signal Detection Single arm PD 1 TNBC SCLC pancreatic gastric bladder Ovarian Mono and Combo | E.R. Squibb & Sons, L.L.C. | $24,840 | 1 |
| Phase I IIA FIH Nivo Combination with Monotherapy Run in | E.R. Squibb & Sons, L.L.C. | $22,020 | 1 |
| Phase III Nivo Ipi Combo in 1L Bladder FA OS nivo CT Substudy | E.R. Squibb & Sons, L.L.C. | $20,790 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RAMUCIRUMAB PLUS DOCETAXEL VERSUS PLACEBO PLUS DOCETAXEL IN PATIENTS WITH LOCALLY ADVANCED OR UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA WHO PROGRESSED ON OR AFTER PLATINUM-BASED THERAPY | Eli Lilly and Company | $18,240 | 2 |
| Phase I IIA FIH Nivo Combination with Monotherapy Run-in | E.R. Squibb & Sons, L.L.C. | $18,240 | 3 |
| Phase IIB 1L NSCLC nivo ipi and nivo ipi chemo | E.R. Squibb & Sons, L.L.C. | $17,475 | 4 |
| Phase III 1L Gastric (nivo+ipi vs nivo+CT vs CT) | E.R. Squibb & Sons, L.L.C. | $12,465 | 2 |
| Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS & 9th DMC) | E.R. Squibb & Sons, L.L.C. | $12,000 | 1 |
| Phase II Nivo orc Nivo combo in mCRC MSI-H & non MSI-H - A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon Cancer | E.R. Squibb & Sons, L.L.C. | $11,588 | 2 |
| Phase IIB 1L NSCLC nivo ipi and nivo ipi chemo - A Study of Nivolumab in Combination with Ipilimumab (part 1); and Nivolumab plus Ipilimumab in Combination with Chemotherapy (part 2) as First Line Therapy in Stage IV Non- Small Cell Lung Cancer (NSCLC) | E.R. Squibb & Sons, L.L.C. | $4,680 | 1 |
| Phase III 1L Esophageal (Nivo+Ipi vs Nivo+CT vs CT) | E.R. Squibb & Sons, L.L.C. | $4,170 | 2 |
| Ph III MIBC Nivo NKTR vs Nivo mono - A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR-214), Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Ci | E.R. Squibb & Sons, L.L.C. | $3,975 | 1 |
| 1L NSCLC DX ALL COMER NON SQUAMOUS | Genentech, Inc. | $3,750 | 1 |
| Phase II III 1L CRC Nivo CT w pt segmentation rational combos - An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer | E.R. Squibb & Sons, L.L.C. | $2,670 | 1 |
| Ph III MIBC (Nivo/NKTR vs Nivo mono) - A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR-214), Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are | E.R. Squibb & Sons, L.L.C. | $1,635 | 1 |
| Phase III 1L Combo SCLC Consolidation LD ED non-progressors - A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive- Stage Disease Small | E.R. Squibb & Sons, L.L.C. | $840.00 | 1 |
| Phase II/III 1L MSS CRC Nivo+ SOC vs SOC - An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer | E.R. Squibb & Sons, L.L.C. | $750.00 | 1 |
| Phase IIB Signal Detection Single arm, PD-1 (TNBC, SCLC, pancreatic, gastric, bladder, Ovarian) Mono and Combo | E.R. Squibb & Sons, L.L.C. | $250.00 | 2 |
| Ph III MIBC (Nivo/NKTR vs Nivo mono) | E.R. Squibb & Sons, L.L.C. | $225.00 | 1 |
| An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (CheckMate 9X8) | E.R. Squibb & Sons, L.L.C. | $75.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,064 | 1,094 | $170,425 | $38,295 |
| 2022 | 18 | 973 | 986 | $165,389 | $38,179 |
| 2021 | 18 | 1,573 | 1,628 | $252,373 | $60,659 |
| 2020 | 19 | 1,251 | 1,299 | $201,418 | $50,443 |
Total Patients
4,861
Total Services
5,007
Medicare Billing
$187,576
Procedure Codes
79
All Medicare Procedures & Services
79 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 65 | 66 | $27,544 | $6,582 | 23.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2023 | 90 | 92 | $25,852 | $5,993 | 23.2% |
| 76705 | Limited ultrasound scan of abdomen | Facility | 2023 | 166 | 171 | $16,245 | $3,817 | 23.5% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Facility | 2023 | 141 | 143 | $17,160 | $3,711 | 21.6% |
| 76536 | Ultrasound scan of head and neck soft tissue | Facility | 2023 | 165 | 170 | $15,300 | $3,372 | 22.0% |
| 76700 | Complete ultrasound scan of abdomen | Facility | 2023 | 71 | 73 | $9,636 | $2,128 | 22.1% |
| 76776 | Ultrasound scan of transplanted kidney | Facility | 2023 | 58 | 69 | $8,211 | $2,021 | 24.6% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Facility | 2023 | 29 | 29 | $7,772 | $1,839 | 23.7% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Office | 2023 | 20 | 20 | $7,510 | $1,735 | 23.1% |
| 10005 | Fine needle aspiration biopsy using ultrasound guidance, first growth | Facility | 2023 | 26 | 26 | $6,266 | $1,566 | 25.0% |
| 76872 | Ultrasound scan of pelvic region through rectum | Facility | 2023 | 59 | 59 | $6,844 | $1,440 | 21.0% |
| 93976 | Ultrasound of abdomen and pelvis artery and vein blood flow | Facility | 2023 | 31 | 31 | $6,169 | $935.18 | 15.2% |
| 76942 | Ultrasonic guidance for needle placement | Facility | 2023 | 30 | 31 | $5,006 | $755.10 | 15.1% |
| 76856 | Complete ultrasound scan of pelvis | Facility | 2023 | 31 | 31 | $3,441 | $628.42 | 18.3% |
| 76830 | Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | Facility | 2023 | 28 | 28 | $3,080 | $561.14 | 18.2% |
| 76882 | Limited ultrasound scan of joint or other extremity structure except blood vessels | Facility | 2023 | 20 | 20 | $1,314 | $548.80 | 41.8% |
| 93971 | Ultrasound study of one arm or leg veins with compression and maneuvers | Facility | 2023 | 19 | 20 | $1,500 | $340.58 | 22.7% |
| 76870 | Ultrasound scan of scrotum | Facility | 2023 | 15 | 15 | $1,575 | $322.61 | 20.5% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2022 | 133 | 134 | $37,654 | $9,017 | 23.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2022 | 67 | 68 | $28,106 | $7,021 | 25.0% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Facility | 2022 | 56 | 56 | $15,008 | $3,753 | 25.0% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Facility | 2022 | 134 | 134 | $16,080 | $3,475 | 21.6% |
| 76705 | Limited ultrasound scan of abdomen | Facility | 2022 | 113 | 115 | $10,925 | $2,448 | 22.4% |
| 76536 | Ultrasound scan of head and neck soft tissue | Facility | 2022 | 111 | 114 | $10,260 | $2,356 | 23.0% |
| 76776 | Ultrasound scan of transplanted kidney | Facility | 2022 | 52 | 57 | $6,783 | $1,676 | 24.7% |
About Dr. Jill Langer, MD
Dr. Jill Langer, MD is a Diagnostic Radiology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003844192.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jill Langer, MD has received a total of $2.5M in payments from pharmaceutical and medical device companies, with $94,098 received in 2024. These payments were reported across 850 transactions from 7 companies. The most common payment nature is "" ($1.3M).
As a Medicare-enrolled provider, Langer has provided services to 4,861 Medicare beneficiaries, totaling 5,007 services with total Medicare billing of $187,576. Data is available for 4 years (2020–2023), covering 79 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Philadelphia, PA
- Active Since 06/29/2006
- Last Updated 05/08/2012
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1003844192
Products in Payments
- OPDIVO (Biological) $1.2M
- KEYTRUDA (Biological) $897,425
- LENVIMA (Drug) $69,405
- WELIREG (Drug) $26,535
- CYRAMZA (Drug) $18,240
- Avastin (Biological) $3,750
- MK-6482 (Drug) $2,430
- MK-7339 (Drug) $150.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Philadelphia
Joan Prowda, Md, MD
Diagnostic Radiology — Payments: $1.7M
Diagnostic Radiology $1.7M
Lisa Jones, Md, MD
Diagnostic Radiology — Payments: $1.3M
Diagnostic Radiology $1.3M
Evan Siegelman, Md, MD
Diagnostic Radiology — Payments: $1.2M
Diagnostic Radiology $1.2M
Parvati Ramchandani, Md, MD
Diagnostic Radiology — Payments: $971,832
Diagnostic Radiology $971,832
Dr. Steven Finden, M.d, M.D
Diagnostic Radiology — Payments: $664,346
Diagnostic Radiology $664,346
Dr. Patrick O'kane, M.d, M.D
Diagnostic Radiology — Payments: $584,199
Diagnostic Radiology $584,199